Novartis AG entered into a clinical collaboration with Bristol-Myers Squibb Co. to evaluate Mekinist in combination with Opdivo and the Opdivo+Yervoy regimen as potential treatments for metastatic colorectal cancer patients with microsatellite stable tumors where the tumors are proficient in mismatch repair.
Colorectal cancer is cancer that starts in the colon or rectum.
Bristol-Myers will conduct phase 1 and 2 studies and will be responsible for determining the recommended dose regimens. The company is also expected to identify the preliminary anti-tumor activity of the combination therapies.
Both companies will assess the results and decide on the optimal approaches and potential clinical development of the drug combinations.